Immunocore Holdings plc
Immunocore Holdings is a United Kingdom-headquartered biotechnology company developing and commercializing T-cell receptor-based immunotherapies. Its platform uses engineered soluble T-cell receptors to engage immune mechanisms against targeted diseased cells. The company's therapeutic work includes oncology and investigational approaches for autoimmune and infectious diseases. Immunocore's shares trade on Nasdaq under IMCR, while the company's operational headquarters are in Oxfordshire, England. This concise profile records its technology and disease-area orientation rather than continually tracking the stages of individual programs.
Company at a glance
Corporate information
- Company entity
- Immunocore Holdings plc
- Headquarters / principal office
- United Kingdom
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.immunocore.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq: IMCR
T-cell receptor therapeutics · soluble bispecific immunotherapies
oncology · autoimmune disease · infectious disease
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Immunocore Holdings is a United Kingdom-headquartered biotechnology company developing and commercializing T-cell receptor-based immunotherapies. Its platform uses engineered soluble T-cell receptors to engage immune mechanisms against targeted diseased cells. The company's therapeutic work includes oncology and investigational approaches for autoimmune and infectious diseases. Immunocore's shares trade on Nasdaq under IMCR, while the company's operational headquarters are in Oxfordshire, England. This concise profile records its technology and disease-area orientation rather than continually tracking the stages of individual programs.
Business, technology & evidence
- SecuritiesNasdaq: IMCR
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Immunocore Holdings plc ↗Immunocore Holdings plc ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.